MX2013010524A - Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata. - Google Patents
Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata.Info
- Publication number
- MX2013010524A MX2013010524A MX2013010524A MX2013010524A MX2013010524A MX 2013010524 A MX2013010524 A MX 2013010524A MX 2013010524 A MX2013010524 A MX 2013010524A MX 2013010524 A MX2013010524 A MX 2013010524A MX 2013010524 A MX2013010524 A MX 2013010524A
- Authority
- MX
- Mexico
- Prior art keywords
- prostate cancer
- combination
- mammalian subject
- hsp90 inhibitor
- oligonucleotide
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 5
- 206010060862 Prostate cancer Diseases 0.000 title abstract 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 5
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 title abstract 4
- 102000003780 Clusterin Human genes 0.000 abstract 4
- 108090000197 Clusterin Proteins 0.000 abstract 4
- 101710113864 Heat shock protein 90 Proteins 0.000 abstract 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 abstract 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona un método para tratar un sujeto mamífero afectado por cáncer de próstata que comprende i) un oligonucleótido que reduce la expresión de clusterina y ii) un inhibidor de la Proteína de Choque de Calor 90 (Hsp9O) cada uno en una cantidad que cuando en combinación con el otro es efectivo para tratar el sujeto mamífero. La presente invención también proporciona composiciones farmacéuticas que comprenden una cantidad de un oligonucleótido que reduce la expresión de clusterina, y un inhibidor Hsp9O para uso al tratar un sujeto mamífero afectado por cáncer de próstata. También se proporcionan oligonucleótidos que reducen la expresión de clusterina para uso en combinación con un inhibidor Hsp9O al tratar un sujeto mamífero afectado por cáncer de próstata, y una composición para tratar un sujeto mamífero afectado por cáncer de próstata que comprende i) un oligonucleótido que reduce la expresión de clusterina y ii) un inhibidor Hsp9O cada uno en una cantidad que cuando en combinación con el otro es efectivo para tratar el sujeto mamífero.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161453102P | 2011-03-15 | 2011-03-15 | |
| PCT/IB2012/000696 WO2012123823A1 (en) | 2011-03-15 | 2012-03-12 | Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013010524A true MX2013010524A (es) | 2013-12-06 |
Family
ID=46830101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013010524A MX2013010524A (es) | 2011-03-15 | 2012-03-12 | Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9457045B2 (es) |
| EP (1) | EP2685990A4 (es) |
| JP (1) | JP2014509608A (es) |
| KR (1) | KR20140038388A (es) |
| AU (1) | AU2012228010B2 (es) |
| BR (1) | BR112013023452A2 (es) |
| CA (1) | CA2830195A1 (es) |
| IL (1) | IL227719A0 (es) |
| MX (1) | MX2013010524A (es) |
| RU (1) | RU2013145869A (es) |
| SG (1) | SG192957A1 (es) |
| WO (1) | WO2012123823A1 (es) |
| ZA (1) | ZA201307560B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ513757A (en) | 1999-02-26 | 2004-12-24 | Univ British Columbia | Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells |
| US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| KR20140038388A (ko) | 2011-03-15 | 2014-03-28 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 전립선암의 치료를 위한 항-클러스테린 올리고뉴클레오타이드와 hsp90 저해제의 병용 |
| US9738643B2 (en) | 2012-08-06 | 2017-08-22 | Duke University | Substituted indazoles for targeting Hsp90 |
| WO2016040809A1 (en) * | 2014-09-11 | 2016-03-17 | Esanex, Inc. | Indazolyl- and indolyl-benzamide derivatives |
| WO2017184956A1 (en) * | 2016-04-22 | 2017-10-26 | Duke University | Compounds and methods for targeting hsp90 |
| US12030867B2 (en) | 2018-05-30 | 2024-07-09 | University Of Notre Dame Du Lac | Hsp90β selective inhibitors |
| WO2023023189A2 (en) * | 2021-08-17 | 2023-02-23 | University Of Virginia Patent Foundation | Clusterin overexpression in alzheimer's disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6383808B1 (en) | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
| NZ513757A (en) | 1999-02-26 | 2004-12-24 | Univ British Columbia | Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells |
| US6900187B2 (en) | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| US7285541B2 (en) | 2002-08-21 | 2007-10-23 | The University Of British Columbia | Treatment of melanoma by reduction in clusterin levels |
| US8710020B2 (en) | 2004-04-02 | 2014-04-29 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
| EP1814595B1 (en) | 2004-11-23 | 2014-01-08 | The University Of British Columbia | Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels |
| NZ588960A (en) | 2005-02-25 | 2012-06-29 | Serenex Inc | Tetrahydroindolone and tetrahydroindazolone derivatives |
| WO2006124904A2 (en) | 2005-05-16 | 2006-11-23 | Geron Corporation | Cancer treatment by combined inhibition of telomerase and hsp90 activities |
| JP2013510585A (ja) | 2009-11-13 | 2013-03-28 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 癌の同定、評価、予防および治療のための組成物、キットおよび方法 |
| WO2012123820A1 (en) | 2011-03-14 | 2012-09-20 | The University Of British Columbia | Combination of anti-clusterin oligonucleotide with androgen receptor antagonist for the treatment of prostate cancer |
| KR20140038388A (ko) | 2011-03-15 | 2014-03-28 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 전립선암의 치료를 위한 항-클러스테린 올리고뉴클레오타이드와 hsp90 저해제의 병용 |
| AU2012257487A1 (en) | 2011-05-19 | 2014-01-16 | Teva Pharmaceutical Industries Ltd. | Method for treating non-small cell lung cancer |
| UY34812A (es) | 2012-05-18 | 2013-12-31 | Teva Pharma | Método para el tratamiento del cáncer de pulmón de células no pequeñas |
-
2012
- 2012-03-12 KR KR1020137027226A patent/KR20140038388A/ko not_active Withdrawn
- 2012-03-12 EP EP12757133.9A patent/EP2685990A4/en not_active Withdrawn
- 2012-03-12 MX MX2013010524A patent/MX2013010524A/es not_active Application Discontinuation
- 2012-03-12 JP JP2013558527A patent/JP2014509608A/ja active Pending
- 2012-03-12 AU AU2012228010A patent/AU2012228010B2/en not_active Ceased
- 2012-03-12 US US14/005,186 patent/US9457045B2/en not_active Expired - Fee Related
- 2012-03-12 BR BR112013023452A patent/BR112013023452A2/pt not_active IP Right Cessation
- 2012-03-12 CA CA2830195A patent/CA2830195A1/en not_active Abandoned
- 2012-03-12 WO PCT/IB2012/000696 patent/WO2012123823A1/en not_active Ceased
- 2012-03-12 SG SG2013064647A patent/SG192957A1/en unknown
- 2012-03-12 RU RU2013145869/15A patent/RU2013145869A/ru not_active Application Discontinuation
-
2013
- 2013-09-16 IL IL227719A patent/IL227719A0/en unknown
- 2013-10-10 ZA ZA2013/07560A patent/ZA201307560B/en unknown
-
2016
- 2016-05-23 US US15/162,158 patent/US20170145418A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL227719A0 (en) | 2013-09-30 |
| US20170145418A1 (en) | 2017-05-25 |
| US9457045B2 (en) | 2016-10-04 |
| BR112013023452A2 (pt) | 2016-12-06 |
| NZ616474A (en) | 2015-06-26 |
| US20140080895A1 (en) | 2014-03-20 |
| SG192957A1 (en) | 2013-09-30 |
| EP2685990A1 (en) | 2014-01-22 |
| AU2012228010A1 (en) | 2013-10-31 |
| RU2013145869A (ru) | 2015-04-20 |
| JP2014509608A (ja) | 2014-04-21 |
| AU2012228010B2 (en) | 2016-08-25 |
| EP2685990A4 (en) | 2014-09-17 |
| ZA201307560B (en) | 2015-06-24 |
| WO2012123823A1 (en) | 2012-09-20 |
| CA2830195A1 (en) | 2012-09-20 |
| KR20140038388A (ko) | 2014-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013010524A (es) | Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata. | |
| PH12013502487A1 (en) | Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents | |
| MY183661A (en) | Treatment of cancer with tor kinase inhibitors | |
| UA115983C2 (uk) | Інгібітори днк-пк | |
| MY162903A (en) | Methods of treatment of pancreatic cancer | |
| WO2013030778A3 (en) | Organic compositions to treat hsf1-related diseases | |
| SG178873A1 (en) | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors | |
| SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| NZ700759A (en) | Combination therapy for treating cancer | |
| MX363243B (es) | Composiciones para tratar cáncer y usos de dichas composiciones. | |
| IN2012DN03883A (es) | ||
| BR112013002012A2 (pt) | métodos e composições para terapia de câncer de fígado | |
| GB2503852A (en) | Compounds for the treatment of neuropsychiatric disorders | |
| MX2014002967A (es) | Antagonistas de los productos del agrupamiento de unigenes hs.459642 para la inhibicion de la proliferacion, del desarrollo o de la diferenciacion de las celulas madre incluyendo las celulas madre cancerosas. | |
| MX2013010530A (es) | Combinacion de oligonucleotido anti-clusterina con antagonistas del receptor de androgeno para el tratamiento de cancer de prostata. | |
| SG10201810575WA (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| PH12014500536A1 (en) | Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors | |
| MX2013015347A (es) | Terapia direccionada al receptor del factor de crecimiento epidermico (egfr). | |
| MX2015012063A (es) | Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer. | |
| WO2013066485A3 (en) | Compositions and methods for treatment of metastatic cancer | |
| WO2012135814A3 (en) | Microrna29a,b,c as a tumor suppressor and sensitizing agent for chemotherapy | |
| WO2011103028A3 (en) | Compositions and methods for inhibiting mmset | |
| NZ629475A (en) | Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines | |
| WO2011128434A3 (en) | Treatment of endocrine resistant breast cancer | |
| WO2008067526A3 (en) | Compositions and methods of sphingosine kinase inhibitors in radiation therapy of various cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |